HC Wainwright keeps Roivant at Buy; raises PT to $47
HC Wainwright & Co. maintained Roivant Sciences at Buy and raised its price target to $47.00 per share from $41.00,
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.